| Stage | CLH | % of rev | FLS | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $1.9B | 100.00% | $1.2B | 100.00% | CLH ×1.51 |
| Gross profit | $661M | 35.38% | $414M | 33.48% | CLH +1.9pp |
| Operating income | $318M | 17.02% | $155M | 12.49% | CLH +4.5pp |
| Pre-tax income | $282M | 15.10% | $122M | 9.87% | CLH +5.2pp |
| Net income | $208M | 11.13% | $107M | 8.65% | CLH +2.5pp |
| Stage | CLH | FLS | Gap · A − B |
|---|---|---|---|
| Revenue | $1.9B100.00% | $1.2B100.00% | CLH ×1.51 |
| Gross profit | 35.38%$661M | 33.48%$414M | CLH +1.9pp |
| Operating income | 17.02%$318M | 12.49%$155M | CLH +4.5pp |
| Pre-tax income | 15.10%$282M | 9.87%$122M | CLH +5.2pp |
| Net income |
| 11.13%$208M |
| 8.65%$107M |
| CLH +2.5pp |
None
No disclosed counterparties: CLH.